Vital Therapies (VTL) Reports Q4 Loss of $0.35/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
March 13, 2018 4:01 PM EDT- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12- On Track for Release of Topline Results in Third Quarter of 2018
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) --  Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and fiscal year ended December 31, 2017.
As VTL-308 nears completion, I am proud of the job our... More
